Tsimafeyeu Ilya
Bureau for Cancer Research - BUCARE, New York, NY 10032, USA.
Explor Target Antitumor Ther. 2025 Jun 20;6:1002327. doi: 10.37349/etat.2025.1002327. eCollection 2025.
Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in the progression of various cancers through its involvement in cell proliferation, survival, and differentiation. More recently, FGFR1 has been implicated in the mechanisms of immune evasion, particularly its role in resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Targeting FGFR1 with monoclonal antibodies and tyrosine kinase inhibitors has emerged as a promising therapeutic strategy to enhance ICI efficacy by altering the tumor microenvironment and countering immune suppression. Preclinical studies demonstrate that combining FGFR1 inhibitors, such as the novel monoclonal antibody OM-RCA-01, with ICIs significantly improves antitumor activity, enhancing T cell responses and cytokine production. This article explores the role of FGFR1 in cancer biology, its contribution to immunotherapy resistance, and the therapeutic potential of targeting FGFR1 to enhance the efficacy of ICIs.
成纤维细胞生长因子受体1（FGFR1）通过参与细胞增殖、存活和分化，在多种癌症的进展中发挥关键作用。最近，FGFR1与免疫逃逸机制有关，特别是其在对派姆单抗和纳武单抗等免疫检查点抑制剂（ICI）耐药中的作用。用单克隆抗体和酪氨酸激酶抑制剂靶向FGFR1已成为一种有前景的治疗策略，可通过改变肿瘤微环境和对抗免疫抑制来提高ICI疗效。临床前研究表明，将FGFR1抑制剂，如新型单克隆抗体OM-RCA-01，与ICI联合使用可显著提高抗肿瘤活性，增强T细胞反应和细胞因子产生。本文探讨了FGFR1在癌症生物学中的作用、其对免疫治疗耐药的影响以及靶向FGFR1以提高ICI疗效的治疗潜力。
